GSK Pharma Names Ronojit Biswas as New CFO, Juby Chandy Moves to APAC Role
New Delhi: GlaxoSmithKline (GSK) Pharmaceuticals Limited has approved the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer (CFO) for a term of three years effective April 1, 2026, while current CFO Juby Chandy will step down from his roles following his elevation within the GSK Group.
The decision was taken by the Board of Directors at its meeting held on March 2, 2026, and disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ronojit Biswas will take over as Whole-Time Director and CFO from April 1, 2026. The company clarified that he is not related to any of the existing directors and is not debarred from holding the office of director by virtue of any order passed by SEBI or any other authority.
A seasoned finance professional with over 25 years of experience at GSK across international markets, Biswas began his career with the company in India as a Management Trainee in 1999. Over the years, he has held several senior global and regional leadership roles across India, Vietnam, Singapore, Brazil, and the United Kingdom. Most recently, he served as Senior Finance Director – Global Product Strategy, based in Singapore. He has also previously served as CFO for GSK’s Brazil and Vietnam businesses and as Regional Controller for GSK’s International region, where he led financial reporting, performance management, and internal controls.
Biswas holds a Post Graduate Program in Management (Finance) from the Management Development Institute, Gurgaon, and a Bachelor’s degree in Commerce (Hons.) from St. Xavier’s College, Kolkata.
Meanwhile, Juby Chandy will step down from his roles as Whole-Time Director and CFO effective March 11, 2026, following his promotion to lead APAC Finance within the GSK Group. The company placed on record its sincere appreciation for Chandy’s contributions, noting his role in strengthening the company’s financial position, enhancing governance standards, and delivering key strategic priorities during a transformative phase.
Also Read: GSK Nucala receives positive EMA Committee opinion for COPD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.